Veradermics Inc(MANE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:40 PM ET (Korea 10/31 07:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 28.54% | Shs Outstand | 41.8M | Perf Week | 0.66% |
| Market Cap | 5.84B | Forward P/E | - | EPS next Y | 8.3% | Insider Trans | -7.46% | Shs Float | 29.9M | Perf Month | 19.17% |
| Enterprise Value | 5.02B | PEG | - | EPS next Q | -0.6 | Inst Own | 70.26% | Short Float | 12.39% | Perf Quarter | 37.1% |
| Income | - | P/S | - | EPS this Y | 16.73% | Inst Trans | 22.95% | Short Ratio | 4.67 | Perf Half Y | 38.31% |
| Sales | - | P/B | 7.17 | EPS next 5Y | 22.01% | ROA | - | Short Interest | 3.70M | Perf YTD | 310.85% |
| Book/sh | 19.49 | P/C | 7.12 | EPS past 3/5Y | -117.94% - | ROE | - | 52W High | -4.7% ($146.57) | Perf Year | - |
| Cash/sh | 19.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 336.53% ($32.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 4.29% 7.18% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 7.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 70.53 | EPS Q/Q | -44.05% | Profit Margin | - | RSI (14) | 62.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 70.53 | Sales Q/Q | - | SMA20 | 9.94% ($127.06) | Beta | - | Target Price | $170.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | 21.91% ($114.58) | Rel Volume | 0.59 | Prev Close | $143.85 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 11.4% - | SMA200 | 48.86% ($93.84) | Avg Volume(3M) | 0.79M | Price | $139.69 |
| IPO | 2026/2/4 | Option/Short | Yes/Yes | Trades | 6347 | Volume | 465,112 | Change | -2.89% |
A clinical-stage biopharmaceutical company developing treatments for dermatological conditions. Its lead candidate is an oral, extended-release minoxidil targeting male and female pattern hair loss, which has shown positive Phase 3 clinical results and is being advanced toward commercialization. The company specializes in dermatological therapeutics, including hair loss treatments.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +16.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 70.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #45 of 597 in the industry
Based on market cap of $6B.
BLTE#43 Belite Bio Inc ADR $6B PER - 
IMVT#44 Immunovant Inc $6B PER - MANE#45 Veradermics Inc $6B PER - 
CGON#46 Cg Oncology Inc $6B PER - 
MIRM#47 Mirum Pharmaceuticals Inc $6B PER - 
FAQ
What kind of company is MANE?
MANE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MANE?
The market cap of MANE is approximately $5.8B, ranking 1,244 within its sector.
What is the 52-week high and low for MANE?
MANE has recorded a 52-week high of $146.57 and a low of $32.00.
